Table 1.
Baseline Characteristics of the Patients
| Variables | All Patients (n = 40) | Mild CIPN Patients (n = 33) | Severe CIPN Patients (n = 7) | p |
|---|---|---|---|---|
| Median age (years ± SD) | 55.38 ± 11.88 | 54.85 ± 2.08 | 57.86 ± 4.53 | 0.63 |
| Gender | 0.06 | |||
| Male (%) | 24 (60) | 22 (66.7) | 2 (28.6) | |
| Female (%) | 16 (40) | 11 (33.3) | 5 (71.4) | |
| BMI (kg/m2 ± SD) | 22.88 ± 4.35 | 23.21 ± 0.76 | 21.28 ± 1.64 | 0.17 |
| BSA (m2 ± SD) | 1.67 ± 0.18 | 1.69 ± 0.03 | 1.56 ± 0.07 | 0.10 |
| Cancer type | 0.56 | |||
| DLBCL (%) | 31 (77.5) | 25 (75.8) | 6 (85.7) | |
| Indolent lymphoma (%) | 9 (22.5) | 8 (24.2) | 1 (14.3) | |
| Disease stage | 0.53 | |||
| Limited (I–II) (%) | 15 (37.5) | 11 (33.3) | 4 (57.1) | |
| Advanced (III–IV) (%) | 21 (52.5) | 18 (54.5) | 3 (42.9) | |
| Missing* (%) | 4 (10.0) | 4 (12.2) | 0 (0) | |
| LDH ± SD | 295.43 ± 154.45 | 303.34 ± 27.5 | 259.29 ± 58.78 | 0.21 |
| Missing* (%) | 1 (0.03) | |||
| ECOG PS | 1.00 | |||
| 0–1 (%) | 24 (60.0) | 20 (60.6) | 4 (57.1) | |
| 2–4 (%) | 6 (15.0) | 5 (15.1) | 1 (14.3) | |
| Missing (%) | 10 (25.0) | 8 (24.3) | 2 (28.6) | |
| Dose VCR per cycle (mg) | 1.98 ± 0.10 | 1.98 ± 0.01 | 1.99 ± 0.04 | 0.71 |
CIPN, chemotherapy-induced peripheral neuropathy; BMI, body mass index; BSA, body surface area; DLBCL, diffuse large B-cell lymphoma; ECOG PS, performance status according to Eastern Collaborative Oncology Group; VCR, dose of vincristine.
*
Some data were lacking on the medical records.